Latest news

• Daiichi Sankyo licenses clot-busting antibody

  The Japanese drugmaker is already a major player in the thrombosis market with products such as Eli Lilly-partnered antiplatelet drug Effient (prasugrel) and recently-introduced NOAC Lixiana (edoxaban).

• FDA gives the nod to TMC's antiplatelet drug

  The drug is an intravenously-administered P2Y12 inhibitor - in the same class as AstraZeneca's Brilinta (ticagrelor) and Daiichi Sankyo/Eli Lilly's Effient (prasugrel) - and like its peers is moving

• FDA reviewer backs approval of TMC's cangrelor

  Cangrelor is a P2Y12 inhibitor - in the same class as AstraZeneca's Brilinta (ticagrelor) and Daiichi Sankyo/Eli Lilly's Effient (prasugrel) - and like its counterparts is aiming to tap into

• AZ seeks leg up in antiplatelet market with Brilinta antidote

  Brilinta (sold as Brilique in Europe) also has competition in the form of Eli Lilly and Daiichi Sankyo's Effient (prasugrel), although the latter has been held back by a higher

• Lilly’s Efient and Sucampo's Amitiza win NICE backing

  on Lilly's Efient (prasugrel) to include people with acute coronary syndromes. ... Taking these factors into consideration, we are now recommending prasugrel as an option for more people with acute coronary syndromes than our previous guidance,” said